Systematic review finds point-of-care testing improves G6PD deficiency detection in malaria patients, indicating safer treatments.
Quantitative point-of-care testing using STANDARD G6PD Biosensor demonstrates superior diagnostic performance, particularly for identifying intermediate G6PD activity, supporting its preferential use for guiding safe radical cure with 8-aminoquinoline therapies in malaria-endemic settings.
No takes yet. Share an insight, caveat, or question.
Unnikrishnan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: